Table 2.
Studies of EUS-Guided Ethanol Ablation for PCLs.
| Author, Year | n | Ethanol Concentration | Type of Cyst | Outcomes | Adverse Events (%) | |
|---|---|---|---|---|---|---|
| Partial Resolution | Complete Resolution | |||||
| Gan 2005 [18] | 23 | 5–80% | IPMN (3), MCN (14), SCN (3), PC (1), Unknown (2) | 9% | 35% | None |
| Dewitt 2009 [19] | 25 | 80% | IPMN (10), MCN (10), SCN (3), PC (2) | - | 33% | 4% pancreatitis, 4% bleeding, 20% abdominal pain |
| DiMaio 2011 [20] | 13 | 80% | IPMN (13) | - | 38% | 8% abdominal pain |
| Caillol 2012 [22] | 13 | 99% | MCN (13) | - | 85% | 0% |
| Park 2016 [23] | 91 | 99% | IPMN (9), MCN (12), SCN (33), PC (9), Indeterminate (28) | 41% | 45% | 3% pancreatitis, 20% abdominal pain, 9% fever |
| Gomez 2016 [21] | 23 | 80% | IPMN (15), MCN (4), non-mucinous (4) | 44% | 9% | 4% pancreatitis, 4% abdominal pain |
| Choi 2019 [24] | 214 | - | IPMN (63), MCN (57), SCN (69), PC (25) | 44% | 25% | 10% pancreatitis, 23% abdominal pain, 1% duodenal stricture |
IPMN: intraductal papillary mucinous neoplasms; SCN: serous cystic neoplasm; MCN: mucinous cystic neoplasm; SC: serous cystadenoma; PC: pseudocyst.